Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme
The Lancet Journal, Volume 397, Issue 10274, February 2021, Pages 581-591